CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

  • Current Quote
  • Stock Chart
$0.38-0.00 (2.56%)
Day High:$0.39
Day Low:$0.37
09/26/164:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345


Recent News

Sep 22, 2016CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule
SEATTLE, Sept. 22, 2016 /PRNewswire/ --  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that on September 20, 2016, the NASDAQ Listing Qualifications staff granted the Company an additional 180 calendar day period, or until March 20, 2017, to regain compliance with the Minimum Bid Price Rule. To do so, the bid price of the Company's common stock must close at or above $1.00 per share for a minimum of 10 consecutive trading days prior to that date.  About CTI BioPha... 
Printer Friendly Version
Aug 29, 2016CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis
Trial demonstrates statistically significant improvement in spleen volume reduction (SVR) with pacritinib compared to best available therapy (BAT), including ruxolitinib Oral pacritinib is the only JAK2 inhibitor evaluated in a randomized clinical trial in patients with thrombocytopenia (<100,000 platelets) to demonstrate a significant improvement in SVR, including in patients who had inadequate responses on marketed anti-JAK2 or failed prior anti-JAK2 SEATTLE, Aug. 29, 2016 /PRNewswi... 
Printer Friendly Version
Aug 04, 2016CTI BioPharma Reports Second Quarter 2016 Financial Results
SEATTLE, Aug. 4, 2016 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the second quarter ended June 30, 2016. "The interest from oncologists generated by the Phase 3 PERSIST-1 long-term safety and efficacy results of pacritinib showing durable reduction in spleen volume and symptom burden including in patients that crossed over to pacritinib from best available therapy, presented at ASCO, supports our belief that pacritinib may play an important ... 
Printer Friendly Version


There are no past events to display.
Data provided by Nasdaq. Minimum 15 minutes delayed.